{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:32:00Z","timestamp":1794490320249,"version":"4.9.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.eururo.2020.07.003","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T01:37:25Z","timestamp":1597196245000},"page":"635-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":195,"title":["Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy"],"prefix":"10.1016","volume":"79","author":[{"given":"Jeffrey J.","family":"Leow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yew Lam","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a P.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.07.003_bib0005","series-title":"European Association of Urology Guidelines Office","article-title":"EAU Guidelines on upper urinary tract urothelial carcinoma 2020. European Association of Urology Guidelines 2020 edition","author":"Roupr\u00eat","year":"2020"},{"key":"10.1016\/j.eururo.2020.07.003_bib0010","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0020","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1464-410X.2006.06524.x","article-title":"Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?","volume":"98","author":"Brown","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S225301","article-title":"Optimal management of upper tract urothelial carcinoma: current perspectives","volume":"13","author":"Leow","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.eururo.2020.07.003_bib0030","series-title":"Spiess PE, for the NCCN Guidelines Panel. NCCN guidelines version 3.2020 for bladder cancer","author":"Flaig","year":"2020"},{"key":"10.1016\/j.eururo.2020.07.003_bib0035","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol."},{"key":"10.1016\/j.eururo.2020.07.003_bib0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/jco.2014.32.4_suppl.309","article-title":"Targeted sequencing of upper tract urothelial carcinoma","volume":"32","author":"Sfakianos","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000126","article-title":"Upper tract urothelial carcinoma: a different disease entity in terms of management","volume":"1","author":"Leow","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2020.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","article-title":"A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma","volume":"67","author":"Seisen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.eururo.2012.11.050","article-title":"The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study","volume":"65","author":"Tanaka","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0065","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.eururo.2012.01.021","article-title":"Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"61","author":"Cha","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eururo.2011.09.017","article-title":"The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy","volume":"61","author":"Chromecki","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0075","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ctrv.2015.02.006","article-title":"A contemporary review of management and prognostic factors of upper tract urothelial carcinoma","volume":"41","author":"Leow","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2020.07.003_bib0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0085","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2020.07.003_bib0090","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2020.07.003_bib0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000092930","article-title":"Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract","volume":"77","author":"Lee","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.urolonc.2012.11.014","article-title":"Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome","volume":"32","author":"Yafi","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.eururo.2020.07.003_bib0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2020.07.003_bib0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.eururo.2020.07.003_bib0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2020.07.003_bib0125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0130","author":"Wells"},{"key":"10.1016\/j.eururo.2020.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/jjco\/hys166","article-title":"A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy","volume":"42","author":"Kitamura","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/iju.13010","article-title":"Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes","volume":"23","author":"Kobayashi","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0145","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1245\/s10434-019-08128-7","article-title":"Neoadjuvant chemotherapy benefits survival in high-grade upper tract urothelial carcinoma: a propensity score-based analysis","volume":"27","author":"Chen","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0150","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.euf.2017.03.013","article-title":"Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma","volume":"4","author":"Hosogoe","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2020.07.003_bib0155","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0160","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","article-title":"Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma","volume":"116","author":"Matin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0165","doi-asserted-by":"crossref","first-page":"101500","DOI":"10.18632\/oncotarget.21551","article-title":"Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study","volume":"8","author":"Kubota","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2020.07.003_bib0170","first-page":"e999","article-title":"LBA-17 Multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma","volume":"201","author":"Coleman Jonathan","year":"2019","journal-title":"J Urol"},{"issue":"4 suppl","key":"10.1016\/j.eururo.2020.07.003_bib0175","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/jco.2014.32.4_suppl.326","article-title":"Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma","volume":"32","author":"Hoffman-Censits","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0180","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0185","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cncr.27751","article-title":"A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results","volume":"119","author":"Siefker-Radtke","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0190","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000282755","article-title":"Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract","volume":"55","author":"Igawa","year":"1995","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0200","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1016\/j.clgc.2018.08.003","article-title":"Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery","volume":"16","author":"Almassi","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/diagnostics10010010","article-title":"Down-grading of ipsilateral hydronephrosis by neoadjuvant chemotherapy correlates with favorable oncological outcomes in patients undergoing radical nephroureterectomy for ureteral carcinoma","volume":"10","author":"Miyake","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.eururo.2020.07.003_bib0210","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JU.0000000000000737","article-title":"Efficacy of preoperative chemotherapy in high-risk upper tract urothelial carcinoma (UTUC)","volume":"203","author":"Foerster","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0215","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1200\/JCO.2018.36.6_suppl.407","article-title":"Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)","volume":"36","author":"Birtle","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0220","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1464-410X.2012.11413.x","article-title":"Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC)\u2014opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) trial","volume":"110","author":"Birtle","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0225","first-page":"3158","article-title":"[Prospective controlled observation of effect of adjuvant chemotherapy on survival and prognosis of high-risk upper tract urothelial carcinoma patients underwent radical nephroureterectomy]","volume":"99","author":"Luo","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.eururo.2020.07.003_bib0230","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group trial","volume":"31","author":"Ito","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0235","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.2004.09.043","article-title":"Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group","volume":"22","author":"Bamias","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0240","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1442-2042.2008.02114.x","article-title":"Adjuvant methotrexate, vinblastine, Adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma","volume":"15","author":"Soga","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0245","doi-asserted-by":"crossref","first-page":"686","DOI":"10.7150\/jca.7326","article-title":"The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma","volume":"4","author":"Kim","year":"2013","journal-title":"J Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0250","first-page":"333","article-title":"Adjuvant radiotherapy for stage III\/IV urothelial carcinoma of the upper tract","volume":"34","author":"Jwa","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2020.07.003_bib0255","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bju.12369","article-title":"Predictors of survival in patients with disease recurrence after radical nephroureterectomy","volume":"113","author":"Kluth","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0260","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.urolonc.2013.06.015","article-title":"High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy","volume":"32","author":"Raman","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0265","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bju.12801","article-title":"The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study","volume":"116","author":"Lucca","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0270","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urolonc.2014.04.006","article-title":"Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration","volume":"32","author":"Fradet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0275","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2015.03.077","article-title":"The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma","volume":"194","author":"Huang","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0280","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1590\/S1677-5538.IBJU.2015.0009","article-title":"Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National University Hospital experience","volume":"41","author":"Kim","year":"2015","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0285","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12894-017-0305-4","article-title":"Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis","volume":"17","author":"Fujita","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4111\/kju.2015.56.1.41","article-title":"Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy","volume":"56","author":"Lee","year":"2015","journal-title":"Korean J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0295","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bju.14020","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0300","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.juro.2014.10.022","article-title":"Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience","volume":"193","author":"Shirotake","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0305","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00345-017-2032-6","article-title":"Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study","volume":"35","author":"Nakagawa","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0310","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","article-title":"Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma","volume":"35","author":"Seisen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0315","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3346\/jkms.2017.32.2.335","article-title":"Impact of the ASA physical status score on adjuvant chemotherapy eligibility and survival of upper tract urothelial carcinoma patients: a multicenter study","volume":"32","author":"Kang","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.eururo.2020.07.003_bib0320","doi-asserted-by":"crossref","first-page":"e1055","DOI":"10.1016\/j.clgc.2017.07.009","article-title":"Predictors for intravesical recurrence following radical nephroureterectomy for upper tract urothelial carcinoma: a national multicenter analysis","volume":"15","author":"Lee","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0325","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1016\/j.clgc.2017.10.014","article-title":"Selected high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy for adjuvant chemotherapy: a multi-institutional retrospective study","volume":"16","author":"Ikeda","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0330","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00432-019-03020-z","article-title":"Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy","volume":"145","author":"Song","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0335","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijsu.2019.04.013","article-title":"Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: a retrospective cohort study","volume":"66","author":"Song","year":"2019","journal-title":"Int J Surg"},{"key":"10.1016\/j.eururo.2020.07.003_bib0340","first-page":"1341","article-title":"Outcomes of stage II-IV upper-tract urothelial carcinoma and adjuvant chemotherapy for locally advanced cancer","volume":"17","author":"Chang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.eururo.2020.07.003_bib0345","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.7150\/jca.34103","article-title":"Role of adjuvant chemotherapy in advanced stage upper urinary tract urothelial carcinoma after radical nephroureterectomy: competing risk analysis after propensity score-matching","volume":"10","author":"Kang","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0350","doi-asserted-by":"crossref","unstructured":"Matsunaga T., Komura K., Hashimoto T., et al. Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort. World J Urol. In press. https:\/\/doi.org\/10.1007\/s00345-020-03118-x.","DOI":"10.1007\/s00345-020-03118-x"},{"key":"10.1016\/j.eururo.2020.07.003_bib0355","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ijrobp.2019.03.027","article-title":"Adjuvant treatments for advanced stage, non-metastatic upper tract urothelial carcinoma: a multicenter study","volume":"104","author":"Kim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.07.003_bib0360","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.07.003_bib0365","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/iju.14068","article-title":"Clinical staging of upper urinary tract urothelial carcinoma for T staging: Review and pictorial essay","volume":"26","author":"Honda","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0370","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","article-title":"Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy","volume":"58","author":"Kaag","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0375","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11934-013-0307-z","article-title":"The role of systemic chemotherapy in management of upper tract urothelial cancer","volume":"14","author":"Gayed","year":"2013","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2020.07.003_bib0380","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0385","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/iju.12868","article-title":"Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: a multi-institutional, retrospective study","volume":"22","author":"Fujita","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0390","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00345-012-0939-5","article-title":"Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma","volume":"31","author":"Fajkovic","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0395","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.hoc.2014.10.003","article-title":"Diagnosis and management of upper tract urothelial carcinoma","volume":"29","author":"Lucca","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.eururo.2020.07.003_bib0400","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/cncr.25043","article-title":"Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy","volume":"116","author":"Lane","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0405","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bju.12597","article-title":"Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"114","author":"Kaag","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.07.003_bib0410","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2020.07.003_bib0415","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2020.07.003_bib0420","doi-asserted-by":"crossref","first-page":"v358","DOI":"10.1093\/annonc\/mdz249.003","article-title":"Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)","volume":"30","author":"Van der Heijden","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0425","doi-asserted-by":"crossref","first-page":"e1835","DOI":"10.1016\/S1569-9056(19)31329-6","article-title":"PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for patients with localized high-risk urothelial carcinoma of the upper urinary tract (UTUC)","volume":"18","author":"Necchi","year":"2019","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2020.07.003_bib0430","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0435","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","article-title":"Kidney complications of immune checkpoint inhibitors: a review","volume":"74","author":"Shingarev","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eururo.2020.07.003_bib0440","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2020.38.15_suppl.5000","article-title":"IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC)","volume":"38","author":"Hussain","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0445","author":"MedicineMatters Oncology"},{"key":"10.1016\/j.eururo.2020.07.003_bib0450","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2020.07.003_bib0455","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/cncr.32806","article-title":"Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and\/or cell-free DNA results","volume":"126","author":"Pal","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.07.003_bib0460","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s10147-020-01650-9","article-title":"Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"25","author":"Quhal","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.critrevonc.2019.01.019","article-title":"Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"135","author":"Kim","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2020.07.003_bib0470","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1016\/j.clgc.2019.08.010","article-title":"Effects of adjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"17","author":"Kim","year":"2019","journal-title":"Clin Genitourin Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820305327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820305327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:08:51Z","timestamp":1759583331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283820305327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0302283820305327"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}